指南与共识颈动脉与弓上血管

支持血管外科学会颈动脉疾病管理指南的系统综述

A systematic review supporting the Society for Vascular Surgery Guidelines on the management of carotid artery disease.
指南 / 共识 · J Vasc Surg · 2021-06-19

血管外科学会写作委员会为制定颈动脉疾病管理指南,系统检索多个数据库,围绕五个临床问题(无症状患者药物与CEA、症状性低手术风险患者CEA与CAS、急性卒中后血运重建时机、高危患者筛查、颈动脉合并冠心病干预顺序)进行系统综述与荟萃分析。结论支持CEA在长期预防卒中/死亡上优于药物和经股CAS,急性卒中后2-14天行CEA,多危险因素增加筛查价值。

要点

  • 无症状患者CEA长期(5年)卒中/死亡显著低于药物治疗。
  • 症状性低手术风险患者CEA的30天卒中风险低于CAS,但心梗风险显著增加。
  • 急性卒中后CEA宜在2至14天进行,多危险因素提升颈动脉筛查价值。

核心结论

  • CEA在长期预防卒中/死亡方面优于药物治疗。
  • 症状性低手术风险患者中CEA在长期减少卒中/死亡方面优于经股CAS。
  • CEA最佳时机为急性卒中发生后2至14天。
  • 多个危险因素可增加颈动脉筛查的价值。

研究设计与样本

  • 由血管外科学会写作委员会委托的系统综述。
  • 检索多个数据库,针对五个临床问题筛选研究,由独立评审配对评估,可行时行荟萃分析。
  • 采用四项随机试验的个体患者数据预计划汇总分析比较经股CAS与CEA。

主要发现

  • 无症状患者药物管理在最初30天早期结局更好,但CEA在5年长期卒中/死亡率显著更低。
  • 症状性低手术风险患者CEA的30天卒中风险低于CAS,但心梗显著增加。
  • 四项随机试验个体数据汇总分析示,术后120天内死亡或卒中风险CEA为5.5%,CAS为8.7%。
  • 急性卒中后48小时内CEA与第2至14天CEA在30天结局无统计学显著差异;注册数据显示第一周CEA结果良好,但48小时内不佳。
  • 除外周动脉疾病外,单一危险因素与低颈动脉筛查检出率相关,多危险因素大幅提高筛查检出率。

关键数值与推荐

  • 无症状患者CEA长期(5年)卒中/死亡率显著低于药物管理。
  • 症状性低手术风险患者CEA的30天卒中风险低于CAS,但心梗显著增加;120天内死亡或卒中风险CEA 5.5% vs CAS 8.7%。
  • 急性卒中后CEA宜在2至14天进行。
  • 多个危险因素增加颈动脉筛查价值。

临床怎么用

  • 无症状颈动脉狭窄患者应权衡CEA长期获益与围手术期风险。
  • 症状性低手术风险患者选择CEA时需权衡较低卒中风险与较高心梗风险。
  • 急性卒中后CEA宜安排在2至14天,避免48小时内手术。
  • 对多危险因素人群可加强颈动脉筛查。

局限性

  • 颈动脉合并冠心病干预时机的证据稀疏且不精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To support the development of guidelines on the management of carotid disease, a writing committee from the Society for Vascular Surgery has commissioned this systematic review. METHODS: We searched multiple data bases for studies addressing five questions: medical management vs carotid revascularization (CEA) in asymptomatic patients, CEA vs carotid artery stenting (CAS) in symptomatic low surgical risk patients, the optimal timing of revascularization after acute stroke, screening high-risk patients for carotid disease, and the optimal sequence of interventions in patients with combined coronary and carotid disease. Studies were selected and appraised by pairs of independent reviewers. Meta-analyses were performed when feasible. RESULTS: Medical management compared with carotid interventions in asymptomatic patients was associated with better early outcome during the first 30 days. However, CEA was associated with significantly lower long-term rate of stroke/death at 5 years. In symptomatic low-risk surgical patients, CEA was associated with a lower risk of stroke, but a significant increase in myocardial infarction compared with CAS during the first 30 days. When the long-term outcome of transfemoral CAS vs CEA in symptomatic patients were examined using preplanned pooled analysis of individual patient data from four randomized trials, the risk of death or stroke within 120 days of the index procedure was 5.5% for CEA and 8.7% for CAS, which lends support that, over the long term, CEA has a superior outcome compared with transfemoral CAS. When managing acute stroke, the comparison of CEA during the first 48 hours to that between day 2 and day 14 did not reveal a statistically significant difference on outcomes during the first 30 days. Registry data show good results with CEA performed in the first week, but not within the first 48 hours. A single risk factor, aside from peripheral artery disease, was associated with low carotid screening yield. Multiple risk factors greatly increase the yield of screening. Evidence on the timing of interventions in patients with combined carotid and coronary disease was sparse and imprecise. Patients without carotid symptoms, who had the carotid intervention first, compared with a combined carotid intervention and coronary artery bypass grafting, had better outcomes. CONCLUSIONS: This updated evidence summary supports the Society for Vascular Surgery clinical practice guidelines for commonly raised clinical scenarios. CEA was superior to medical therapy in the long-term prevention of stroke/death over medical therapy. CEA was also superior to transfemoral CAS in minimizing long-term stroke/death for symptomatic low risk surgical patients. CEA should optimally be performed between 2 and 14 days from the onset of acute stroke. Having multiple risk factors increases the value of carotid screening.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hasan B, Farah M, Nayfeh T, et al. A systematic review supporting the Society for Vascular Surgery Guidelines on the management of carotid artery disease. J Vasc Surg. 2021. PMID: 34153350. doi:10.1016/j.jvs.2021.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。